MRX-6

DRUG2 trials

Sponsors

Hadassah Medical Organization, Celsus Therapeutics PLC

Conditions

Allergic Contact DermatitisAtopic Dermatitis

Phase 1

Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis

CompletedNCT00867607

Hadassah Medical OrganizationAllergic Contact Dermatitis

Start: 2011-03-31End: 2014-03-31Updated: 2015-04-21

Phase 2

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

TerminatedNCT02031445

Celsus Therapeutics PLCAtopic Dermatitis

Start: 2014-08-31End: 2015-03-31Updated: 2016-05-06